(FIE) Fielmann Aktiengesellschaft - Ratings and Ratios
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE0005772206
FIE: Glasses, Frames, Lenses, Sunglasses, Hearing Aids
Fielmann Group AG stands as a leader in the optical and hearing aid sectors across Europe, operating in Germany, Switzerland, Austria, and beyond. Their comprehensive product line includes eyewear, contact lenses, sunglasses, and hearing aids, all under well-known brands such as fielmann and Optika Clarus. This diversification not only broadens their market reach but also strengthens their position in the health care equipment industry.
The companys distribution strategy is a blend of modern and traditional, utilizing retail stores, their e-commerce platform, and partnerships to ensure wide accessibility. This multi-channel approach caters to a broad customer base, enhancing their competitive edge in a rapidly evolving market. Notably, Fielmann Group AG is a subsidiary of Korva SE, underscoring its robust corporate structure.
Financially, Fielmann Group AG presents an intriguing profile with a market capitalization of 3657.92M EUR. The trailing P/E ratio of 26.08 and forward P/E of 16.53 suggest expectations of future growth. The price-to-book ratio of 3.78 indicates a premium, reflecting investor confidence in their intangible assets and brand value. The price-to-sales ratio of 1.70 aligns with industry peers, indicating efficient sales performance.
Investors should consider Fielmanns vertically integrated model, which streamlines production and distribution, potentially boosting margins. Their expansion into hearing aids taps into a growing market, driven by an aging population and increased health awareness. With a focus on innovation, Fielmann is well-positioned to capitalize on rising demand in both optics and audiology, making them a compelling option for those seeking exposure to the health care equipment sector.
Additional Sources for FIE Stock
FIE Stock Overview
Market Cap in USD | 4,195m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception |
FIE Stock Ratings
Growth 5y | -20.4% |
Fundamental | 69.8% |
Dividend | 15.4% |
Rel. Strength Industry | 5.38 |
Analysts | - |
Fair Price Momentum | 44.12 EUR |
Fair Price DCF | 53.92 EUR |
FIE Dividends
Dividend Yield 12m | 2.32% |
Yield on Cost 5y | 2.26% |
Annual Growth 5y | -12.50% |
Payout Consistency | 93.9% |
FIE Growth Ratios
Growth Correlation 3m | 64.6% |
Growth Correlation 12m | -1.6% |
Growth Correlation 5y | -65.4% |
CAGR 5y | -0.11% |
CAGR/Max DD 5y | 0.00 |
Sharpe Ratio 12m | -0.20 |
Alpha | 1.81 |
Beta | 0.10 |
Volatility | 41.70% |
Current Volume | 61k |
Average Volume 20d | 32.8k |
As of March 13, 2025, the stock is trading at EUR 44.00 with a total of 61,041 shares traded.
Over the past week, the price has changed by -2.65%, over one month by +1.50%, over three months by +7.32% and over the past year by +5.28%.
Yes, based on ValueRay Fundamental Analyses, Fielmann Aktiengesellschaft (XETRA:FIE) is currently (March 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 69.80 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of FIE as of March 2025 is 44.12. This means that FIE is currently overvalued and has a potential downside of 0.27%.
Fielmann Aktiengesellschaft has no consensus analysts rating.
According to ValueRays Forecast Model, FIE Fielmann Aktiengesellschaft will be worth about 47.7 in March 2026. The stock is currently trading at 44.00. This means that the stock has a potential upside of +8.3%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 56.6 | 28.6% |
Analysts Target Price | - | - |
ValueRay Target Price | 47.7 | 8.3% |